farmaecFARMAKOEKONOMIKA. Modern Pharmacoeconomics and PharmacoepidemiologyФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология2070-49092070-4933IRBIS LLC10.17749/2070-4909/farmakoekonomika.2021.113farmaec-632Research ArticleREVIEW ARTICLESОБЗОРНЫЕ ПУБЛИКАЦИИProspects of using chondroprotectors for the treatment of pulmonary pathologyПерспективы применения хондропротекторов для лечения легочной патологииhttps://orcid.org/0000-0002-2659-7998ТоршинИ. Ю.TorshinI. Yu.

Торшин Иван Юрьевич – к.ф-м.н., к.х.н., старший научный сотрудник

WoS ResearcherID: C-7683-2018

Scopus Author ID: 7003300274

РИНЦ SPIN-код: 1375-1114 

ул. Вавилова, д. 4, Москва 119333

Ivan Yu. Torshin – PhD (Phys. Math.), PhD (Chem.), Senior Researcher

WoS ResearcherID: C-7683-2018

Scopus Author ID: 7003300274

RSCI SPIN-code: 1375-1114 

4 Vavilov Str., Moscow 119333

https://orcid.org/0000-0002-7663-710XГромоваО. А.GromovaO. A.

Громова Ольга Алексеевна – д.м.н., профессор, научный руководитель

WoS ResearcherID: J-4946-2017

Scopus Author ID: 7003589812

РИНЦ SPIN-код: 6317-9833 

ул. Вавилова, д. 4, Москва 119333

Olga A. Gromova – Dr. Med. Sc., Professor, Research Supervisor

WoS ResearcherID: J-4946-2017

Scopus Author ID: 7003589812

RSCI SPIN-code: 6317-9833 

4 Vavilov Str., Moscow 119333

unesco.gromova@gmail.comhttps://orcid.org/0000-0002-5070-5450ЧучалинА. Г.ChuchalinA. G.

Чучалин Александр Григорьевич – д.м.н., профессор, академик РАН, пульмонолог, заведующий кафедрой госпитальной терапии педиатрического факультета

РИНЦ SPIN-код: 7742-2054 

ул. 1-я Леонова, д. 16, Москва 129226

Aleksandr G. Chuchalin – Dr. Med. Sc., Professor, Academician of RAS, Pulmonologist, Chief of Chair of Hospital Therapy, Faculty of Pediatrics

RSCI SPIN-code: 7742-2054 

16 Pervaya Leonov Str., Moscow 129226

Федеральный исследовательский центр «Информатика и управление» Российской академии наукРоссияFederal Research Center “Informatics and Management”, Russian Academy of SciencesRussian FederationФедеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Министерства здравоохранения Российской ФедерацииРоссияPirogov Russian National Research Medical UniversityRussian Federation202116012022144563579Copyright © Torshin I.Y., Gromova O.A., Chuchalin A.G., 20222022Торшин И.Ю., Громова О.А., Чучалин А.Г.Torshin I.Y., Gromova O.A., Chuchalin A.G.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacoeconomics.ru/jour/article/view/632

Background. The complex mechanisms of action of chondroitin sulfate (CS) and glucosamine sulfate (GS) at the molecular level make it possible to assert the applicability of the corresponding drugs far beyond chondroprotection. Inhibition of proinflammatory mechanisms (NF-κB, activation of toll-receptors, increased levels of cytokines, degranulation of mast cells, etc.) by CS and GS provide the prospects for their use to inhibit inflammation in the respiratory tracts, allergic processes and to enhance the effects of glucocorticoids.Objective: to systemize data on the effects of chondroitin sulfate and glucosamine sulfate on pathophysiological processes in pulmonary pathology.Material and methods. Using the methods of the theory of text topological analysis an intellectual analysis of 1273 publications on fundamental and clinical studies of the relationship of CS and GS with lung function was carried out. The search was performed by a key query “(glucosamine OR chondroitin) AND (lung OR lungs OR pulmonary OR pulmonology)” in the Pubmed/MEDLINE database. As a result, 59 informative biomedical terms were identified.Results. The chemoproteomic study of CS and GS showed that their intake promoted an increase in the expression of 19 antitumor proteins and a decrease in the expression of 25 pro-inflammatory proteins involved in lung function. CS and GS can be used in the complex therapy of infectious diseases of the lungs, with fibrotic changes in the respiratory tracts and, as well, help to reduce the risk of neoplastic diseases of the lungs.Conclusion. The results of this analysis allow us to assert the promising nature of the use of CS and GS in several neoplastic diseases of the lungs, as well as the high safety of drugs based on pharmaceutical standardized forms of CS and GS in terms of lung function.

Актуальность. Комплексные механизмы действия хондроитина сульфата (ХС) и глюкозамина сульфата (ГС) на молекулярном уровне позволяют утверждать, что соответствующие препараты применимы далеко за пределами хондропротекции. Ингибирование провоспалительных механизмов (NF-κB, активация толл-рецепторов, повышение уровней цитокинов, дегрануляция тучных клеток и др.) посредством ХС и ГС обусловливает перспективы их применения для торможения процессов воспаления в дыхательных путях и аллергических процессов, а также для усиления эффектов глюкокортикоидов.Цель: систематизация данных об эффектах хондроитина сульфата и глюкозамина сульфата на патофизиологические процессы при легочной патологии.Материал и методы. Методами теории топологического анализа текстов проведен интеллектуальный анализ 1273 публикаций по фундаментальным и клиническим исследованиям взаимосвязей ХС и ГС с функцией легких. Поиск статей осуществляли по ключевому запросу “(glucosamine OR chondroitin) AND (lung OR lungs OR pulmonary OR pulmonology)” в базе биомедицинских публикаций Pubmed/MEDLINE. В результате было выделено 59 информативных биомедицинских терминов.Результаты. Хемопротеомное исследование ХС и ГС показало, что их прием способствует повышению экспрессии 19 противоопухолевых белков и снижению экспрессии 25 провоспалительных белков, вовлеченных в функционирование легких. ХС и ГС могут использоваться в комплексной терапии инфекционных заболеваний легких, при фибротических изменениях дыхательных путей, а также позволяют снизить риск опухолевых заболеваний легких.Заключение. Результаты анализа указывают на перспективность применения ХС и ГС при ряде опухолевых заболеваний легких и высокую безопасность препаратов на основе фармацевтических стандартизированных форм ХС и ГС с точки зрения функции легких.

хондропротекцияпротеомболезни легкихфиброзхондроитина сульфатглюкозамина сульфаттопологический анализ данныхchondroprotectionproteomelung diseasesfibrosischondroitin sulfateglucosamine sulfatetopological data analysisРабота выполнена по гранту Российского научного фонда (проект № 20-12-00175) в Ивановском государственном химико-технологическом университете.This work was financially supported by the grant of the Russian Science Foundation (No. 20-12-00175) in Ivanovo State University of Chemistry and Technology.ReferencesReginato A.M., Riera H., Vera M., et al. Osteoarthritis in Latin America: study of demographic and clinical characteristics in 3040 patients. J Clin Rheumatol. 2015; 21 (8): 391–7. https://doi.org/10.1097/RHU.0000000000000281.Reginato A.M., Riera H., Vera M., et al. Osteoarthritis in Latin America: study of demographic and clinical characteristics in 3040 patients. J Clin Rheumatol. 2015; 21 (8): 391–7. https://doi.org/10.1097/RHU.0000000000000281.Торшин И.Ю., Лила А.М., Лиманова О.А., Громова О.А. Перспективы применения хондроитина сульфата и глюкозамина сульфата при остеоартрите в сочетании с патологией почек и мочевыделительной системы. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020; 13 (1): 23–34. https://doi.org/10.17749/2070-4909.2020.13.1.23-34.Torshin I.Yu., Lila A.M., Limanova O.A., Gromova O.A. Prospects for the use of chondroitin sulfate and glucosamine sulfate in osteoarthritis in combination with pathology of the kidneys and urinary system. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020; 13 (1): 23–34 (in Russ.). https://doi.org/10.17749/2070-4909.2020.13.1.23-34.Торшин И.Ю., Лила А.М., Наумов А.В. и др. Перспективы персонификации профилактики и терапии остеоартрита на основании анализа коморбидного фона, генетических полиморфизмов и микроэлементного статуса. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2021; 14 (1): 28–39. https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.077.Torshin I.Yu., Lila A.M., Naumov A.V., et al. Perspectives of personification of prevention and therapy of osteoarthritis based on the analysis of comorbid background, genetic polymorphisms and microelement status. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021; 14 (1): 28–39 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.077.Mendy A., Apewokin S., Wells A.A., Morrow A.L. Factors associated with hospitalization and disease severity in a racially and ethnically diverse population of COVID-19 patients. medRxiv. 2020; Jun 27, 2020. https://doi.org/10.1101/2020.06.25.20137323.Mendy A., Apewokin S., Wells A.A., Morrow A.L. Factors associated with hospitalization and disease severity in a racially and ethnically diverse population of COVID-19 patients. medRxiv. 2020; Jun 27, 2020. https://doi.org/10.1101/2020.06.25.20137323.Bruyère O., Honvo G., Veronese N., et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49 (3): 337–50. https://doi.org/10.1016/j.semarthrit.2019.04.008.Bruyère O., Honvo G., Veronese N., et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49 (3): 337–50. https://doi.org/10.1016/j.semarthrit.2019.04.008.Торшин И.Ю., Громова О.А., Чучалин А.Г., Журавлев Ю.И. Хемореактомный скрининг воздействия фармакологических препаратов на SARS-CoV-2 и виром человека как информационная основа для принятия решений по фармакотерапии COVID-19. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2021; 14 (2): 191–211. https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.078.Torshin I.Yu., Gromova O.A., Chuchalin A.G., Zhuravlev Yu.I. Chemoreactomic screening of the effect of pharmacological drugs on SARS-CoV-2 and human vira as an information basis for making decisions on pharmacotherapy for COVID-19. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021; 14 (2): 191–211 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.078.Shannon J.M., McCormick-Shannon K., Burhans M.S., et al. Chondroitin sulfate proteoglycans are required for lung growth and morphogenesis in vitro. Am J Physiol Lung Cell Mol Physiol. 2003; 285 (6): L1323–36. https://doi.org/10.1152/ajplung.00226.2003.Shannon J.M., McCormick-Shannon K., Burhans M.S., et al. Chondroitin sulfate proteoglycans are required for lung growth and morphogenesis in vitro. Am J Physiol Lung Cell Mol Physiol. 2003; 285 (6): L1323–36. https://doi.org/10.1152/ajplung.00226.2003.Souza-Fernandes A.B., Pelosi P., Rocco P.R. Bench-to-bedside review: the role of glycosaminoglycans in respiratory disease. Crit Care. 2006; 10 (6): 237. https://doi.org/10.1186/cc5069.Souza-Fernandes A.B., Pelosi P., Rocco P.R. Bench-to-bedside review: the role of glycosaminoglycans in respiratory disease. Crit Care. 2006; 10 (6): 237. https://doi.org/10.1186/cc5069.Negrini D., Passi A., Moriondo A. The role of proteoglycans in pulmonary edema development. Intensive Care Med. 2008; 34 (4): 610– 8. https://doi.org/10.1007/s00134-007-0962-y.Negrini D., Passi A., Moriondo A. The role of proteoglycans in pulmonary edema development. Intensive Care Med. 2008; 34 (4): 610– 8. https://doi.org/10.1007/s00134-007-0962-y.Torshin I.Yu., Rudakov K.V. On the procedures of generation of numerical features over partitions of sets of objects in the problem of predicting numerical target variables. Pattern Recognit Image Anal. 2019; 29 (4): 654–67. https://doi.org/10.1134/S1054661819040175.Torshin I.Yu., Rudakov K.V. On the procedures of generation of numerical features over partitions of sets of objects in the problem of predicting numerical target variables. Pattern Recognit Image Anal. 2019; 29 (4): 654–67. https://doi.org/10.1134/S1054661819040175.Torshin I.Y. Optimal dictionaries of the final information on the basis of the solvability criterion and their applications in bioinformatics. Pattern Recognit Image Anal. 2013; 23: 319–27. https://doi.org/10.1134/S1054661813020156.Torshin I.Y. Optimal dictionaries of the final information on the basis of the solvability criterion and their applications in bioinformatics. Pattern Recognit Image Anal. 2013; 23: 319–27. https://doi.org/10.1134/S1054661813020156.Torshin I.Yu., Rudakov K.V. On the theoretical basis of the metric analysis of poorly formalized problems of recognition and classification. Pattern Recognit Image Anal. 2015; 25 (4): 577–87.Torshin I.Yu., Rudakov K.V. On the theoretical basis of the metric analysis of poorly formalized problems of recognition and classification. Pattern Recognit Image Anal. 2015; 25 (4): 577–87.Wu Y.L., Kou Y.R., Ou H.L., et al. Glucosamine regulation of LPS-mediated inflammation in human bronchial epithelial cells. Eur J Pharmacol. 2010; 635 (1-3): 219–26. https://doi.org/10.1016/j.ejphar.2010.02.044.Wu Y.L., Kou Y.R., Ou H.L., et al. Glucosamine regulation of LPSmediated inflammation in human bronchial epithelial cells. Eur J Pharmacol. 2010; 635 (1-3): 219–26. https://doi.org/10.1016/j.ejphar.2010.02.044.Chuang K.H., Peng Y.C., Chien H.Y., et al. Attenuation of LPSinduced lung inflammation by glucosamine in rats. Am J Respir Cell Mol Biol. 2013; 49 (6): 1110–9. https://doi.org/10.1165/rcmb.2013-0022OC.Chuang K.H., Peng Y.C., Chien H.Y., et al. Attenuation of LPSinduced lung inflammation by glucosamine in rats. Am J Respir Cell Mol Biol. 2013; 49 (6): 1110–9. https://doi.org/10.1165/rcmb.2013-0022OC.Rao N.V., Kennedy T.P., Rao G., et al. Sulfated polysaccharides prevent human leukocyte elastase-induced acute lung injury and emphysema in hamsters. Am Rev Respir Dis. 1990; 142 (2): 407–12. https://doi.org/10.1164/ajrccm/142.2.407.Rao N.V., Kennedy T.P., Rao G., et al. Sulfated polysaccharides prevent human leukocyte elastase-induced acute lung injury and emphysema in hamsters. Am Rev Respir Dis. 1990; 142 (2): 407–12. https://doi.org/10.1164/ajrccm/142.2.407.Kantor E.D., Lampe J.W., Navarro S.L., et al. Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation. J Altern Complement Med. 2014; 20 (6): 479– 85. https://doi.org/10.1089/acm.2013.0323.Kantor E.D., Lampe J.W., Navarro S.L., et al. Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation. J Altern Complement Med. 2014; 20 (6): 479– 85. https://doi.org/10.1089/acm.2013.0323.Wang D., DuBois R.N. Urinary PGE-M: a promising cancer biomarker. Cancer Prev Res (Phila). 2013; 6 (6): 507–10. https://doi.org/10.1158/1940-6207.CAPR-13-0153.Wang D., DuBois R.N. Urinary PGE-M: a promising cancer biomarker. Cancer Prev Res (Phila). 2013; 6 (6): 507–10. https://doi.org/10.1158/1940-6207.CAPR-13-0153.Thompson H.L., Schulman E.S., Metcalfe D.D. Identification of chondroitin sulfate E in human lung mast cells. J Immunol. 1988; 140 (8): 2708–13.Thompson H.L., Schulman E.S., Metcalfe D.D. Identification of chondroitin sulfate E in human lung mast cells. J Immunol. 1988; 140 (8): 2708–13.Stevens R.L., Fox C.C., Lichtenstein L.M., Austen K.F. Identification of chondroitin sulfate E proteoglycans and heparin proteoglycans in the secretory granules of human lung mast cells. Proc Natl Acad Sci USA. 1988; 85 (7): 2284–7. https://doi.org/10.1073/pnas.85.7.2284.Stevens R.L., Fox C.C., Lichtenstein L.M., Austen K.F. Identification of chondroitin sulfate E proteoglycans and heparin proteoglycans in the secretory granules of human lung mast cells. Proc Natl Acad Sci USA. 1988; 85 (7): 2284–7. https://doi.org/10.1073/pnas.85.7.2284.Jung A.Y., Heo M.J., Kim Y.H. Glucosamine has an antiallergic effect in mice with allergic asthma and rhinitis. Int Forum Allergy Rhinol. 2017; 7 (8): 763–9. https://doi.org/10.1002/alr.21967.Jung A.Y., Heo M.J., Kim Y.H. Glucosamine has an antiallergic effect in mice with allergic asthma and rhinitis. Int Forum Allergy Rhinol. 2017; 7 (8): 763–9. https://doi.org/10.1002/alr.21967.Chung M.J., Park J.K., Park Y.I. Anti-inflammatory effects of lowmolecular weight chitosan oligosaccharides in IgE-antigen complexstimulated RBL-2H3 cells and asthma model mice. Int Immunopharmacol. 2012; 12 (2): 453–9. https://doi.org/10.1016/j.intimp.2011.12.027.Chung M.J., Park J.K., Park Y.I. Anti-inflammatory effects of lowmolecular weight chitosan oligosaccharides in IgE-antigen complexstimulated RBL-2H3 cells and asthma model mice. Int Immunopharmacol. 2012; 12 (2): 453–9. https://doi.org/10.1016/j.intimp.2011.12.027.Pouvelle B., Meyer P., Robert C., et al. Chondroitin-4-sulfate impairs in vitro and in vivo cytoadherence of Plasmodium falciparum infected erythrocytes. Mol Med. 1997; 3 (8): 508–18.Pouvelle B., Meyer P., Robert C., et al. Chondroitin-4-sulfate impairs in vitro and in vivo cytoadherence of Plasmodium falciparum infected erythrocytes. Mol Med. 1997; 3 (8): 508–18.Bastos M.F., Albrecht L., Kozlowski E.O., et al. Fucosylated chondroitin sulfate inhibits Plasmodium falciparum cytoadhesion and merozoite invasion. Antimicrob Agents Chemother. 2014; 58 (4): 1862– 71. https://doi.org/10.1128/AAC.00686-13.Bastos M.F., Albrecht L., Kozlowski E.O., et al. Fucosylated chondroitin sulfate inhibits Plasmodium falciparum cytoadhesion and merozoite invasion. Antimicrob Agents Chemother. 2014; 58 (4): 1862– 71. https://doi.org/10.1128/AAC.00686-13.Bachman H. Prolonged use of oxytetracycline hydrochloride with glucosamine in twenty-five patients for nonspecific complications associated with pulmonary tuberculosis. Dis Chest. 1960; 38: 303–4. https://doi.org/10.1378/chest.38.3.303.Bachman H. Prolonged use of oxytetracycline hydrochloride with glucosamine in twenty-five patients for nonspecific complications associated with pulmonary tuberculosis. Dis Chest. 1960; 38: 303–4. https://doi.org/10.1378/chest.38.3.303.Rodrigues S., da Costa A.M.R., Flórez-Fernández N., et al. Inhalable spray-dried chondroitin sulphate microparticles: effect of different solvents on particle properties and drug activity. Polymers (Basel). 2020; 12 (2): 425. https://doi.org/10.3390/polym12020425.Rodrigues S., da Costa A.M.R., Flórez-Fernández N., et al. Inhalable spray-dried chondroitin sulphate microparticles: effect of different solvents on particle properties and drug activity. Polymers (Basel). 2020; 12 (2): 425. https://doi.org/10.3390/polym12020425.Hwang J.S., Kim K.H., Park J., et al. Glucosamine improves survival in a mouse model of sepsis and attenuates sepsis-induced lung injury and inflammation. J Biol Chem. 2019; 294 (2): 608–22. https://doi.org/10.1074/jbc.RA118.004638.Hwang J.S., Kim K.H., Park J., et al. Glucosamine improves survival in a mouse model of sepsis and attenuates sepsis-induced lung injury and inflammation. J Biol Chem. 2019; 294 (2): 608–22. https://doi.org/10.1074/jbc.RA118.004638.Vishniakova L.A., Reztsova Iu.V. A method for preventing experimental pneumococcal infection. Zh Mikrobiol Epidemiol Immunobiol. 1997; 2: 20–3.Vishniakova L.A., Reztsova Iu.V. A method for preventing experimental pneumococcal infection. Zh Mikrobiol Epidemiol Immunobiol. 1997; 2: 20–3.Bensadoun E.S., Burke A.K., Hogg J.C., Roberts C.R. Proteoglycan deposition in pulmonary fibrosis. Am J Respir Crit Care Med. 1996; 154 (6 Pt. 1): 1819–28. https://doi.org/10.1164/ajrccm.154.6.8970376.Bensadoun E.S., Burke A.K., Hogg J.C., Roberts C.R. Proteoglycan deposition in pulmonary fibrosis. Am J Respir Crit Care Med. 1996; 154 (6 Pt. 1): 1819–28. https://doi.org/10.1164/ajrccm.154.6.8970376.Yoshida A., Hiramatsu M., Hatakeyama K., Minami N. Elevation of glucosamine 6-phosphate synthetase activity in bleomycin-induced pulmonary fibrosis in hamsters. J Antibiot (Tokyo). 1982; 35 (7): 882–5. https://doi.org/10.7164/antibiotics.35.882.Yoshida A., Hiramatsu M., Hatakeyama K., Minami N. Elevation of glucosamine 6-phosphate synthetase activity in bleomycin-induced pulmonary fibrosis in hamsters. J Antibiot (Tokyo). 1982; 35 (7): 882–5. https://doi.org/10.7164/antibiotics.35.882.Kai Y., Yoneyama H., Yoshikawa M., et al. Chondroitin sulfate in tissue remodeling: therapeutic implications for pulmonary fibrosis. Respir Investig. 2021; 59 (5): 576–88. https://doi.org/10.1016/j.resinv.2021.05.012.Kai Y., Yoneyama H., Yoshikawa M., et al. Chondroitin sulfate in tissue remodeling: therapeutic implications for pulmonary fibrosis. Respir Investig. 2021; 59 (5): 576–88. https://doi.org/10.1016/j.resinv.2021.05.012.Mizumoto S., Sugahara K. Glycosaminoglycans are functional ligands for receptor for advanced glycation end-products in tumors. FEBS J. 2013; 280 (10): 2462–70. https://doi.org/10.1111/febs.12156.Mizumoto S., Sugahara K. Glycosaminoglycans are functional ligands for receptor for advanced glycation end-products in tumors. FEBS J. 2013; 280 (10): 2462–70. https://doi.org/10.1111/febs.12156.Ju Y., Yu A., Sun X., et al. Glucosamine, a naturally occurring amino monosaccharide, inhibits A549 and H446 cell proliferation by blocking G1/S transition. Mol Med Rep. 2013; 8 (3): 794–8. https://doi.org/10.3892/mmr.2013.1584.Ju Y., Yu A., Sun X., et al. Glucosamine, a naturally occurring amino monosaccharide, inhibits A549 and H446 cell proliferation by blocking G1/S transition. Mol Med Rep. 2013; 8 (3): 794–8. https://doi.org/10.3892/mmr.2013.1584.Song K.H., Kang J.H., Woo J.K., et al. The novel IGF-IR/Aktdependent anticancer activities of glucosamine. BMC Cancer. 2014; 14: 31. https://doi.org/10.1186/1471-2407-14-31.Song K.H., Kang J.H., Woo J.K., et al. The novel IGF-IR/Aktdependent anticancer activities of glucosamine. BMC Cancer. 2014; 14: 31. https://doi.org/10.1186/1471-2407-14-31.Liang Y., Xu W., Liu S., et al. N-acetyl-glucosamine sensitizes nonsmall cell lung cancer cells to TRAIL-induced apoptosis by activating death receptor 5. Cell Physiol Biochem. 2018; 45 (5): 2054–70. https://doi.org/10.1159/000488042.Liang Y., Xu W., Liu S., et al. N-acetyl-glucosamine sensitizes nonsmall cell lung cancer cells to TRAIL-induced apoptosis by activating death receptor 5. Cell Physiol Biochem. 2018; 45 (5): 2054–70. https://doi.org/10.1159/000488042.Brezillon S., Zeltz C., Schneider L., et al. Lumican inhibits B16F1 melanoma cell lung metastasis. J Physiol Pharmacol. 2009; 60 (Suppl. 4): 15–22.Brezillon S., Zeltz C., Schneider L., et al. Lumican inhibits B16F1 melanoma cell lung metastasis. J Physiol Pharmacol. 2009; 60 (Suppl. 4): 15–22.Borsig L., Wang L., Cavalcante M.C., et al. Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber. Effect on tumor metastasis and neutrophil recruitment. J Biol Chem. 2007; 282 (20): 14984–91. https://doi.org/10.1074/jbc.M610560200.Borsig L., Wang L., Cavalcante M.C., et al. Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber. Effect on tumor metastasis and neutrophil recruitment. J Biol Chem. 2007; 282 (20): 14984–91. https://doi.org/10.1074/jbc.M610560200.Zhang J.S., Imai T., Otagiri M. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin. Arch Toxicol. 2000; 74 (6): 300–7. https://doi.org/10.1007/s002040000124.Zhang J.S., Imai T., Otagiri M. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin. Arch Toxicol. 2000; 74 (6): 300–7. https://doi.org/10.1007/s002040000124.Lei X., Ma N., Liang Y., et al. Glucosamine protects against radiationinduced lung injury via inhibition of epithelial-mesenchymal transition. J Cell Mol Med. 2020; 24 (18): 11018–23. https://doi.org/10.1111/jcmm.15662.Lei X., Ma N., Liang Y., et al. Glucosamine protects against radiationinduced lung injury via inhibition of epithelial-mesenchymal transition. J Cell Mol Med. 2020; 24 (18): 11018–23. https://doi.org/10.1111/jcmm.15662.Brasky T.M., Lampe J.W., Slatore C.G., White E. Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Causes Control. 2011; 22 (9): 1333–42. https://doi.org/10.1007/s10552-011-9806-8.Brasky T.M., Lampe J.W., Slatore C.G., White E. Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Causes Control. 2011; 22 (9): 1333–42. https://doi.org/10.1007/s10552-011-9806-8.Li G., Zhang X., Liu Y., et al. Relationship between glucosamine use and the risk of lung cancer: data from a nationwide prospective cohort study. Eur Respir J. 2021: 2101399. https://doi.org/10.1183/13993003.01399-2021.Li G., Zhang X., Liu Y., et al. Relationship between glucosamine use and the risk of lung cancer: data from a nationwide prospective cohort study. Eur Respir J. 2021: 2101399. https://doi.org/10.1183/13993003.01399-2021.Navarro S.L., White E., Kantor E.D., et al. Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS One. 2015; 10 (2): e0117534. https://doi.org/10.1371/journal.pone.0117534.Navarro S.L., White E., Kantor E.D., et al. Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS One. 2015; 10 (2): e0117534. https://doi.org/10.1371/journal.pone.0117534.Wang Q., Zhang Y., Zhang T., et al. Low claudin-6 expression correlates with poor prognosis in patients with non-small cell lung cancer. Onco Targets Ther. 2015; 8: 1971–7. https://doi.org/10.2147/OTT.S85478.Wang Q., Zhang Y., Zhang T., et al. Low claudin-6 expression correlates with poor prognosis in patients with non-small cell lung cancer. Onco Targets Ther. 2015; 8: 1971–7. https://doi.org/10.2147/OTT.S85478.Peng Z., Gong Y., Liang X. Role of FAT1 in health and disease. Oncol Lett. 2021; 21 (5): 398. https://doi.org/10.3892/ol.2021.12659.Peng Z., Gong Y., Liang X. Role of FAT1 in health and disease. Oncol Lett. 2021; 21 (5): 398. https://doi.org/10.3892/ol.2021.12659.Foxler D.E., Bridge K.S., James V., et al. The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity. Nat Cell Biol. 2012; 14 (2): 201–8. https://doi.org/10.1038/ncb2424.Foxler D.E., Bridge K.S., James V., et al. The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity. Nat Cell Biol. 2012; 14 (2): 201–8. https://doi.org/10.1038/ncb2424.Zeng X., Wang H., He D., et al. LIMD1 increases the sensitivity of lung adenocarcinoma cells to cisplatin via the GADD45α/p38 MAPK signaling pathway. Front Oncol. 2020; 10: 969. https://doi.org/10.3389/fonc.2020.00969.Zeng X., Wang H., He D., et al. LIMD1 increases the sensitivity of lung adenocarcinoma cells to cisplatin via the GADD45α/p38 MAPK signaling pathway. Front Oncol. 2020; 10: 969. https://doi.org/10.3389/fonc.2020.00969.Cui Y., Liang S., Zhang S., et al. ABCA8 is regulated by miR-374b-5p and inhibits proliferation and metastasis of hepatocellular carcinoma through the ERK/ZEB1 pathway. J Exp Clin Cancer Res. 2020; 39 (1): 90. https://doi.org/10.1186/s13046-020-01591-1.Cui Y., Liang S., Zhang S., et al. ABCA8 is regulated by miR-374b-5p and inhibits proliferation and metastasis of hepatocellular carcinoma through the ERK/ZEB1 pathway. J Exp Clin Cancer Res. 2020; 39 (1): 90. https://doi.org/10.1186/s13046-020-01591-1.Gong M., Li Y., Ye X., et al. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation. Cell Commun Signal. 2020; 18 (1): 98. https://doi.org/10.1186/s12964-020-00568-z.Gong M., Li Y., Ye X., et al. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation. Cell Commun Signal. 2020; 18 (1): 98. https://doi.org/10.1186/s12964-020-00568-z.Salimi U., Menden H.L., Mabry S.M., et al. Angiopoietin-1 protects against endotoxin-induced neonatal lung injury and alveolar simplification in mice. Pediatr Res. 2021; May 12. https://doi.org/10.1038/s41390-021-01544-0.Salimi U., Menden H.L., Mabry S.M., et al. Angiopoietin-1 protects against endotoxin-induced neonatal lung injury and alveolar simplification in mice. Pediatr Res. 2021; May 12. https://doi.org/10.1038/s41390-021-01544-0.Michael I.P., Orebrand M., Lima M., et al. Angiopoietin-1 deficiency increases tumor metastasis in mice. BMC Cancer. 2017; 17 (1): 539. https://doi.org/10.1186/s12885-017-3531-y.Michael I.P., Orebrand M., Lima M., et al. Angiopoietin-1 deficiency increases tumor metastasis in mice. BMC Cancer. 2017; 17 (1): 539. https://doi.org/10.1186/s12885-017-3531-y.Yuan L., Zhang X., Yang M., et al. Airway epithelial integrin β4 suppresses allergic inflammation by decreasing CCL17 production. Clin Sci (Lond). 2020; 134 (13): 1735–49. https://doi.org/10.1042/CS20191188.Yuan L., Zhang X., Yang M., et al. Airway epithelial integrin β4 suppresses allergic inflammation by decreasing CCL17 production. Clin Sci (Lond). 2020; 134 (13): 1735–49. https://doi.org/10.1042/CS20191188.Liu X., Wu S., Xia Y., et al. Wingless homolog Wnt11 suppresses bacterial invasion and inflammation in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2011; 301 (6): G992–1003. https://doi.org/10.1152/ajpgi.00080.2011.Liu X., Wu S., Xia Y., et al. Wingless homolog Wnt11 suppresses bacterial invasion and inflammation in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2011; 301 (6): G992–1003. https://doi.org/10.1152/ajpgi.00080.2011.Khairnar V., Duhan V., Maney S.K., et al. CEACAM1 induces B-cell survival and is essential for protective antiviral antibody production. Nat Commun. 2015; 6: 6217. https://doi.org/10.1038/ncomms7217.Khairnar V., Duhan V., Maney S.K., et al. CEACAM1 induces B-cell survival and is essential for protective antiviral antibody production. Nat Commun. 2015; 6: 6217. https://doi.org/10.1038/ncomms7217.Arcone R., Arpaia G., Ruoppolo M., et al. Structural characterization of a biologically active human lipocortin 1 expressed in Escherichia coli. Eur J Biochem. 1993; 211 (1-2): 347–55. https://doi.org/10.1111/j.1432-1033.1993.tb19904.x.Arcone R., Arpaia G., Ruoppolo M., et al. Structural characterization of a biologically active human lipocortin 1 expressed in Escherichia coli. Eur J Biochem. 1993; 211 (1-2): 347–55. https://doi.org/10.1111/j.1432-1033.1993.tb19904.x.Leoni G., Neumann P.A., Kamaly N., et al. Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. J Clin Invest. 2015; 125 (3): 1215–27. https://doi.org/10.1172/JCI76693.Leoni G., Neumann P.A., Kamaly N., et al. Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. J Clin Invest. 2015; 125 (3): 1215–27. https://doi.org/10.1172/JCI76693.Easter M., Garth J., Harris E.S., et al. Fibroblast growth factor receptor 4 deficiency mediates airway inflammation in the adult healthy lung? Front Med (Lausanne). 2020; 7: 317. https://doi.org/10.3389/fmed.2020.00317.Easter M., Garth J., Harris E.S., et al. Fibroblast growth factor receptor 4 deficiency mediates airway inflammation in the adult healthy lung? Front Med (Lausanne). 2020; 7: 317. https://doi.org/10.3389/fmed.2020.00317.Anderson B.D., Nakamura T., Russell S.J., Peng K.W. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 2004; 64 (14): 4919–26. https://doi.org/10.1158/0008-5472.CAN-04-0884.Anderson B.D., Nakamura T., Russell S.J., Peng K.W. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 2004; 64 (14): 4919–26. https://doi.org/10.1158/0008-5472.CAN-04-0884.Grumelli S., Lu B., Peterson L., et al. CD46 protects against chronic obstructive pulmonary disease. PLoS One. 2011; 6 (5): e18785. https://doi.org/10.1371/journal.pone.0018785.Grumelli S., Lu B., Peterson L., et al. CD46 protects against chronic obstructive pulmonary disease. PLoS One. 2011; 6 (5): e18785. https://doi.org/10.1371/journal.pone.0018785.Szabo R., Netzel-Arnett S., Hobson J.P., et al. Matriptase-3 is a novel phylogenetically preserved membrane-anchored serine protease with broad serpin reactivity. Biochem J. 2005; 390 (Pt. 1): 231–42. https://doi.org/10.1042/BJ20050299.Szabo R., Netzel-Arnett S., Hobson J.P., et al. Matriptase-3 is a novel phylogenetically preserved membrane-anchored serine protease with broad serpin reactivity. Biochem J. 2005; 390 (Pt. 1): 231–42. https://doi.org/10.1042/BJ20050299.Akiyama M., Takeda S., Kokame K., et al. Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci USA. 2009; 106 (46): 19274–9. https://doi.org/10.1073/pnas.0909755106.Akiyama M., Takeda S., Kokame K., et al. Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci USA. 2009; 106 (46): 19274–9. https://doi.org/10.1073/pnas.0909755106.Denorme F., Kraft P., Pareyn I., et al. Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease. PLoS One. 2017; 12 (6): e0179258. https://doi.org/10.1371/journal.pone.0179258.Denorme F., Kraft P., Pareyn I., et al. Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease. PLoS One. 2017; 12 (6): e0179258. https://doi.org/10.1371/journal.pone.0179258.Cao Z., Bhella D., Lindsay J.G. Reconstitution of the mitochondrial PrxIII antioxidant defence pathway: general properties and factors affecting PrxIII activity and oligomeric state. J Mol Biol. 2007; 372 (4): 1022–33. https://doi.org/10.1016/j.jmb.2007.07.018.Cao Z., Bhella D., Lindsay J.G. Reconstitution of the mitochondrial PrxIII antioxidant defence pathway: general properties and factors affecting PrxIII activity and oligomeric state. J Mol Biol. 2007; 372 (4): 1022–33. https://doi.org/10.1016/j.jmb.2007.07.018.Zhen W.Q., Xie Z.Z., Wang X., et al. Influences of PON1 on airway inflammation and remodeling in bronchial asthma. J Cell Biochem. 2018; 119 (1): 793–805. https://doi.org/10.1002/jcb.26242.Zhen W.Q., Xie Z.Z., Wang X., et al. Influences of PON1 on airway inflammation and remodeling in bronchial asthma. J Cell Biochem. 2018; 119 (1): 793–805. https://doi.org/10.1002/jcb.26242.Amatullah H., Maron-Gutierrez T., Shan Y., et al. Protective function of DJ-1/PARK7 in lipopolysaccharide and ventilator-induced acute lung injury. Redox Biol. 2021; 38: 101796. https://doi.org/10.1016/j.redox.2020.101796.Amatullah H., Maron-Gutierrez T., Shan Y., et al. Protective function of DJ-1/PARK7 in lipopolysaccharide and ventilator-induced acute lung injury. Redox Biol. 2021; 38: 101796. https://doi.org/10.1016/j.redox.2020.101796.Richarme G., Liu C., Mihoub M., et al. Guanine glycation repair by DJ-1/Park7 and its bacterial homologs. Science. 2017; 357 (6347): 208–11. https://doi.org/10.1126/science.aag1095.Richarme G., Liu C., Mihoub M., et al. Guanine glycation repair by DJ-1/Park7 and its bacterial homologs. Science. 2017; 357 (6347): 208–11. https://doi.org/10.1126/science.aag1095.Jang B.C., Sung S.H., Park J.G., et al. Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner. J Biol Chem. 2007; 282 (38): 27622–32. https://doi.org/10.1074/jbc.M610778200.Jang B.C., Sung S.H., Park J.G., et al. Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner. J Biol Chem. 2007; 282 (38): 27622–32. https://doi.org/10.1074/jbc.M610778200.Громова О.А., Торшин И.Ю., Лила А.М. и др. Дифференциальный хемореактомный анализ глюкозамина сульфата и нестероидных противовоспалительных препаратов: перспективные синергичные комбинации. Современная ревматология. 2018; 12 (2): 36–43. https://doi.org/10.14412/1996-7012-2018-2-36-43.Gromova O.A., Torshin I.Yu., Lila A.M., et al. Differential chemoreactom analysis of glucosamine sulfate and nonsteroidal antiinflammatory drugs: promising synergistic drug combinations. Modern Rheumatology Journal. 2018; 12 (2): 36–43 (in Russ.). https://doi.org/10.14412/1996-7012-2018-2-36-43.Song P., Xie Z., Wu Y., et al. Protein kinase czeta-dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells. J Biol Chem. 2008; 283 (18): 12446–55. https://doi.org/10.1074/jbc.M708208200.Song P., Xie Z., Wu Y., et al. Protein kinase czeta-dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells. J Biol Chem. 2008; 283 (18): 12446–55. https://doi.org/10.1074/jbc.M708208200.Cheng X., Ma Y., Moore M., et al. Phosphorylation and activation of cAMP-dependent protein kinase by phosphoinositide-dependent protein kinase. Proc Natl Acad Sci USA. 1998; 95 (17): 9849–54. https://doi.org/10.1073/pnas.95.17.9849.Cheng X., Ma Y., Moore M., et al. Phosphorylation and activation of cAMP-dependent protein kinase by phosphoinositide-dependent protein kinase. Proc Natl Acad Sci USA. 1998; 95 (17): 9849–54. https://doi.org/10.1073/pnas.95.17.9849.Reimold A.M., Iwakoshi N.N., Manis J., et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature. 2001; 412 (6844): 300–7. https://doi.org/10.1038/35085509.Reimold A.M., Iwakoshi N.N., Manis J., et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature. 2001; 412 (6844): 300–7. https://doi.org/10.1038/35085509.Ronkina N., Menon M.B., Schwermann J., et al. MAPKAP kinases MK2 and MK3 in inflammation: complex regulation of TNF biosynthesis via expression and phosphorylation of tristetraprolin. Biochem Pharmacol. 2010; 80 (12): 1915–20. https://doi.org/10.1016/j.bcp.2010.06.021.Ronkina N., Menon M.B., Schwermann J., et al. MAPKAP kinases MK2 and MK3 in inflammation: complex regulation of TNF biosynthesis via expression and phosphorylation of tristetraprolin. Biochem Pharmacol. 2010; 80 (12): 1915–20. https://doi.org/10.1016/j.bcp.2010.06.021.Fan C., Rajasekaran D., Syed M.A., et al. MIF intersubunit disulfide mutant antagonist supports activation of CD74 by endogenous MIF trimer at physiologic concentrations. Proc Natl Acad Sci USA. 2013; 110 (27): 10994–9. https://doi.org/10.1073/pnas.1221817110.Fan C., Rajasekaran D., Syed M.A., et al. MIF intersubunit disulfide mutant antagonist supports activation of CD74 by endogenous MIF trimer at physiologic concentrations. Proc Natl Acad Sci USA. 2013; 110 (27): 10994–9. https://doi.org/10.1073/pnas.1221817110.Aung G., Niyonsaba F., Ushio H., et al. Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and chemokines. Immunology. 2011; 132 (4): 527–39. https://doi.org/10.1111/j.1365-2567.2010.03395.x.Aung G., Niyonsaba F., Ushio H., et al. Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and chemokines. Immunology. 2011; 132 (4): 527–39. https://doi.org/10.1111/j.1365-2567.2010.03395.x.Keegan A.D., Nelms K., White M., et al. An IL-4 receptor region containing an insulin receptor motif is important for IL-4-mediated IRS-1 phosphorylation and cell growth. Cell. 1994; 76 (5): 811–20. https://doi.org/10.1016/0092-8674(94)90356-5.Keegan A.D., Nelms K., White M., et al. An IL-4 receptor region containing an insulin receptor motif is important for IL-4-mediated IRS-1 phosphorylation and cell growth. Cell. 1994; 76 (5): 811–20. https://doi.org/10.1016/0092-8674(94)90356-5.Harashima S., Horiuchi T., Wang Y., et al. Sorting nexin 19 regulates the number of dense core vesicles in pancreatic β-cells. J Diabetes Investig. 2012; 3 (1): 52–61. https://doi.org/10.1111/j.2040-1124.2011.00138.x.Harashima S., Horiuchi T., Wang Y., et al. Sorting nexin 19 regulates the number of dense core vesicles in pancreatic β-cells. J Diabetes Investig. 2012; 3 (1): 52–61. https://doi.org/10.1111/j.2040-1124.2011.00138.x.Торшин И.Ю., Лила А.М., Наумов А.В. и др. Метаанализ клинических исследований эффективности лечения остеоартита препаратом Хондрогард. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020; 13 (4): 18–29 https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.066.Torshin I.Yu., Lila A.M., Naumov A.V., et al. Meta-analysis of clinical trials of the effectiveness of treatment of osteoarthitis with Chondrogard. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020; 13 (4): 18–29 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.066.Громова О.А., Торшин И.Ю., Зайчик Б.Ц. и др. О различиях в стандартизации лекарственных препаратов на основе экстрактов хондроитина сульфата. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2021; 14 (1): 40–52. https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.083.Gromova O.A., Torshin I.Yu., Zaichik B.Ts., et al. Differences in the standardization of medicinal products based on extracts of chondroitin sulfate. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021; 14 (1): 40–52 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.083.

The authors declare that there are no conflicts of interest present.